STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer
eLife · 2025
DOI: 10.7554/elife.102433 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Huan Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Transcription Factors, DNA-Binding Proteins, Hypoxia-Inducible Factor 1, alpha Subunit. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Biomedical Projects of Yunnan Key Science and Technology Program.
Abstract (Originalsprache)
In the clinic, anti-tumor angiogenesis is commonly employed for treating recurrent, metastatic, drug-resistant triple-negative, and advanced breast cancer. Our previous research revealed that the deubiquitinase STAMBPL1 enhances the stability of MKP-1, thereby promoting cisplatin resistance in breast cancer. In this study, we discovered that STAMBPL1 could upregulate the expression of the hypoxia-inducible factor HIF1α in breast cancer cells. Therefore, we investigated whether STAMBPL1 promotes tumor angiogenesis. We demonstrated that STAMBPL1 increased HIF1A transcription in a non-enzymatic manner, thereby activating the HIF1α/VEGFA signaling pathway to facilitate triple-negative breast cancer angiogenesis. Through RNA-seq analysis, we identified the transcription factor GRHL3 as a downstream target of STAMBPL1 that is responsible for mediating HIF1A transcription. Furthermore, we discovered that STAMBPL1 regulates GRHL3 transcription by interacting with the transcription factor FOXO1. These findings shed light on the role and mechanism of STAMBPL1 in the pathogenesis of breast cancer, offering novel targets and avenues for the treatment of triple-negative and advanced breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
- Kunming College of Life Sciences, University of Chinese Academy of Sciences, Kunming, China.
- The Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
- Department of Pharmacy, the First People's Hospital of Yunnan Province/the Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
- Academy of Biomedical Engineering, Kunming Medical University, Kunming, China.
- The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
ORCID-Profile: Huan Fang, Huichun Liang, Ceshi Chen
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Biomedical Projects of Yunnan Key Science and Technology Program
- Yunnan Fundamental Research Projects
- Yunnan Revitalization Talent Support Program
- Yunnan (Kunming) Academician Expert Workstation
- Kunming University of Science and Technology-The First People's Hospital of Yunnan Province Joint Major Project
- Center of Clinical Pharmacy of the First People's Hospital of Yunnan Province Open Project
Zitieren
APA
Fang, H., Liang, H., Yang, C., Jiang, D., Luo, Q., Cao, W. M., Zhang, H., & Chen, C. (2025). STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer. eLife. https://doi.org/10.7554/elife.102433
Vancouver
Fang H, Liang H, Yang C, Jiang D, Luo Q, Cao WM, et al. STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer. eLife. 2025. doi:10.7554/elife.102433
BibTeX
@article{Fang2025,
author = {Fang, Huan and Liang, Huichun and Yang, Chuanyu and Jiang, Dewei and Luo, Qianmei and Cao, Wen-Ming and Zhang, Huifeng and Chen, Ceshi},
title = {STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.102433}
}
EUVIMED